We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$130M
Cap. Flow %
-22.12%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$24.8M
2
ABBV icon
AbbVie
ABBV
+$23.3M
3
AGN
Allergan Inc
AGN
+$23M
4
JNJ icon
Johnson & Johnson
JNJ
+$22.1M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 68.95%
2 Miscellaneous 18.46%
3 Technology 5.1%
4 Industrials 3.71%
5 Energy 1.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
126
Akebia Therapeutics
AKBA
$248M
– –
-89,817
Closed -$1.99M
ARCT icon
127
CALL
Arcturus Therapeutics
ARCT
$481M
– –
-8,014
Closed -$866K
ATNM icon
128
Actinium Pharmaceuticals
ATNM
$37.4M
– –
-9,710
Closed -$1.95M
BCLI
129
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-4,222
Closed -$265K
BLRX
130
BioLineRX
BLRX
$12.3M
– –
-322
Closed -$298K
BLUE
131
DELISTED
bluebird bio
BLUE
– –
-4,123
Closed -$1.92M
CL icon
132
Colgate-Palmolive
CL
$69.9B
– –
-40,099
Closed -$2.62M
ENLV icon
133
Enlivex Ltd
ENLV
$12.7M
– –
-250
Closed -$1.09M
GOOG icon
134
Alphabet (Google) Class C
GOOG
$4.2T
– –
-166,937
Closed -$4.85M
INCY icon
135
Incyte
INCY
$25.9B
– –
-61,173
Closed -$3M
IRWD icon
136
Ironwood Pharmaceuticals
IRWD
$699M
– –
-231,875
Closed -$2.52M
JNJ icon
137
Johnson & Johnson
JNJ
$651B
– –
-207,406
Closed -$22.1M
MA icon
138
Mastercard
MA
$496B
– –
-26,000
Closed -$1.92M
MBOT icon
139
Microbot Medical
MBOT
$95.4M
– –
-300
Closed -$612K
MRK icon
140
Merck
MRK
$363B
– –
-437,571
Closed -$24.8M
SLB icon
141
SLB Ltd
SLB
$77.3B
– –
-28,790
Closed -$2.93M
TJX icon
142
CALL
TJX Companies
TJX
$139B
– –
-100,000
Closed -$2.96M
VFC icon
143
VF Corp
VFC
$5.08B
– –
-50,870
Closed -$3.16M
XLV icon
144
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.8B
– –
-485,500
Closed -$31M
XNTK icon
145
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.91B
– –
-400,000
Closed -$39.4M
YUM icon
146
Yum! Brands
YUM
$37B
– –
-55,515
Closed -$2.87M
SMMF
147
DELISTED
Summit Financial Group, Inc.
SMMF
– –
-25,000
Closed -$63K
SGEN
148
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-155,360
Closed -$5.78M
CYTO
149
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-2
Closed -$1.11M
OTIC
150
DELISTED
Otonomy, Inc.
OTIC
– –
-111,085
Closed -$2.67M
3 4 5
6
7

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $130M in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 60% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $14M.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.